IDEXX LABORATORIES INC /DE Revenue from Contract with Customer, Including Assessed Tax
IDEXX LABORATORIES INC /DE (IDXX) reported Revenue from Contract with Customer, Including Assessed Tax of $580.75 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-01.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2018-08-01
- IDEXX LABORATORIES INC /DE revenue from contract with customer, including assessed tax for the quarter ending 2018-06-30 was $580.75M, a 14.11% increase year-over-year.
- IDEXX LABORATORIES INC /DE revenue from contract with customer, including assessed tax for the quarter ending 2018-03-31 was $537.66M, a 16.37% increase year-over-year.
- IDEXX LABORATORIES INC /DE revenue from contract with customer, including assessed tax for the quarter ending 2017-06-30 was $508.94M.
- IDEXX LABORATORIES INC /DE revenue from contract with customer, including assessed tax for the quarter ending 2017-03-31 was $462.02M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month |
|---|---|---|
| 2018-06-30 | $580.75M 10-Q · filed 2018-08-01 | $1.12B 10-Q · filed 2018-08-01 |
| 2018-03-31 | $537.66M 10-Q · filed 2018-05-04 | |
| 2017-06-30 | $508.94M 10-Q · filed 2018-08-01 | $970.96M 10-Q · filed 2018-08-01 |
| 2017-03-31 | $462.02M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |